Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Transactions
Holdings
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed director
CC transcript
Appointed CFO
GILEAD SCIENCES, INC. (GILD) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/16/2023 8-K Investor presentation
Docs: "Byoung Chul Cho, Yonsei Cancer Center, Republic of Korea 2 DRAFT Introduction • PD-1 inhibitor-based regimens have been established as the standard-of-care 1L treatment for mNSCLC,1,2 and novel combination therapies are needed to further improve outcomes • Sacituzumab govitecan is a Trop-2–directed ADC approved in the United States for the treatment of 2L+ mTNBC and pretreated HR+/HER2– mBC, and received accelerated approval for 2L mUC3 • Sacituzumab govitecan has previously demonstrated clinical activity and manageable safety in heavily pretreated patients with mNSCLC4 • EVOKE-02 is an ongoing, multicohort phase 2 study of sacituzumab govitecan + pembrolizumab ± platinum agent in patients with untreated 1L mNSCLC • Here, we report preliminary result..."
08/07/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
08/04/2023 S-3ASR Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers:
08/04/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/03/2023 8-K Quarterly results
Docs: "GILEAD SCIENCES ANNOUNCES SECOND QUARTER 2023 FINANCIAL RESULTS"
07/20/2023 144 Form 144 - Report of proposed sale of securities:
07/06/2023 SC 13D/A GILEAD SCIENCES, INC. reports a 35% stake in ARCUS BIOSCIENCES, INC.
05/05/2023 8-K Quarterly results
04/27/2023 8-K Quarterly results
04/06/2023 PX14A6G Form PX14A6G - Notice of exempt solicitation submitted by non-management:
04/05/2023 DEFR14A Form DEFR14A - Revised definitive proxy soliciting materials:
03/29/2023 PX14A6G Form PX14A6G - Notice of exempt solicitation submitted by non-management:
03/23/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/23/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
02/22/2023 10-K Annual Report for the period ended December 31, 2022
02/14/2023 SC 13G/A GILEAD SCIENCES, INC. reports a 7.2% stake in HOOKIPA PHARMA INC.
02/13/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/13/2023 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
02/09/2023 SC 13G/A VANGUARD GROUP INC reports a 8.9% stake in Gilead Sciences Inc.
02/06/2023 8-K Quarterly results
02/06/2023 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
02/02/2023 8-K Quarterly results
01/31/2023 SC 13G/A BlackRock Inc. reports a 10.5% stake in GILEAD SCIENCES INC
11/02/2022 10-Q Quarterly Report for the period ended September 30, 2022
10/27/2022 8-K Quarterly results
09/12/2022 8-K Regulation FD Disclosure  Interactive Data
08/08/2022 10-Q Quarterly Report for the period ended June 30, 2022
08/05/2022 SC 13G GILEAD SCIENCES, INC. reports a 14.8% stake in ALLOVIR, INC.
08/02/2022 8-K Quarterly results
Docs: "GILEAD SCIENCES ANNOUNCES SECOND QUARTER 2022 FINANCIAL RESULTS"
07/28/2022 8-K Quarterly results
07/08/2022 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
05/31/2022 8-K Quarterly results
05/05/2022 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
05/05/2022 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy